Finch Therapeutics Group, Inc.
FNCHQ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FNCHQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FNCHQ
Finch Therapeutics Group, Inc. is a microbiome technology company that has discontinued its lead clinical program and shifted focus to monetizing its intellectual property estate, with no current expectation of advancing product candidates or generating product revenue.
Key risk: No product revenue expected
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2024.
Tracking 4 pipeline candidates · 1 clinical trial for Finch Therapeutics Group, Inc..
Finch Therapeutics Group, Inc. is a microbiome technology company that has discontinued its lead clinical program and shifted focus to monetizing its intellectual property estate, with no current expectation of advancing product candidates or generating product revenue.
- Finch Therapeutics is a microbiome technology company that discontinued its Phase 3 trial of CP101 for recurrent C. difficile infection in January 2023 and has since focused on realizing value from its intellectual property and other assets [sec_mda · as of 2023-05-10].
- As of June 30, 2024, the company had cash and equivalents of $18.4M, no revenue, a net loss of $4.8M, and an accumulated deficit of $359.1M [sec].
- The company does not currently expect to progress any product candidate through clinical trials or commercial approval, nor does it expect to generate revenue from product sales [sec_mda · as of 2024-08-13].
- Finch holds a pipeline of preclinical assets including FIN-525 for Crohn's disease, and has a biorepository of strains and samples, as well as licensing relationships such as with the University of Minnesota [sec_mda · as of 2023-05-10].
What works
- Finch has a significant biorepository of strains and samples and a portfolio of intellectual property that may be valuable through licensing or partnerships [sec_mda · as of 2023-05-10].
- The company has ongoing investigator-sponsored trials, including one with Brigham and Women's Hospital evaluating CP101 in ulcerative colitis, and a licensing relationship with the University of Minnesota [sec_mda · as of 2023-05-10].
- Finch has reduced its cash burn by winding down development activities, terminating vendor contracts, and reducing headcount, which may extend its cash runway [sec_mda · as of 2023-05-10].
What to weigh
- Finch has discontinued its lead clinical program (CP101 Phase 3 trial) and does not expect to advance any product candidate through clinical trials or to generate product revenue [sec_mda · as of 2024-08-13].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $359.1 million as of June 30, 2024, and expects to continue generating losses [sec_mda · as of 2024-08-13].
- Finch's pipeline is early-stage (preclinical) and faces intense competition, including from major pharmaceutical companies with advanced programs in Crohn's disease [pipeline].
- The company has undergone leadership changes and a strategic reprioritization, indicating operational instability and uncertainty about future direction [sec_mda · as of 2023-05-10].
From the filings
Quoted directly from source documents.
Finch discontinued its Phase 3 trial of CP101 in January 2023 and shifted focus to intellectual property.
“In January 2023, we announced the decision to discontinue our Phase 3 clinical trial of CP101 in recurrent CDI and focus on realizing the value of our intellectual property estate and other assets.”
SEC MD&A · May 10, 2023
Finch does not expect to progress any product candidate or generate product revenue.
“We do not currently expect to be able to progress any product candidate through clinical trials or commercial approval and we do not currently expect to generate any revenue from product sales.”
SEC MD&A · August 13, 2024
As of June 30, 2024, Finch had an accumulated deficit of $359.1 million.
“As of June 30, 2024, we had an accumulated deficit of $359.1 million.”
SEC MD&A · August 13, 2024
Finch has a preclinical pipeline including FIN-525 for Crohn's disease.
“Pipeline Candidate: fin-525 Indication: Crohn's disease Phase: Preclinical”
Risks & what to watch (4)›
Key risks
- No product revenue expected — Company does not expect to generate product revenue or advance candidates to approval [sec_mda · as of 2024-08-13].
- Significant accumulated deficit — Accumulated deficit of $359.1M as of June 30, 2024, with ongoing operating losses [sec_mda · as of 2024-08-13].
- Early-stage pipeline competition — Preclinical pipeline faces competition from large pharma with advanced programs in Crohn's disease [pipeline].
- Leadership and strategic uncertainty — Recent CEO/COO termination and strategic reprioritization create operational instability [sec_mda · as of 2023-05-10].
What to watch
- Any new licensing or partnership agreements that monetize Finch's intellectual property estate [sec_mda · as of 2024-08-13].
- Progress of investigator-sponsored trials, such as the CP101 trial in ulcerative colitis at Brigham and Women's Hospital [sec_mda · as of 2023-05-10].
- Cash runway and burn rate, given the company's reduced spending and no expected revenue [sec_mda · as of 2024-08-13].
- Potential strategic alternatives, including asset sales or further restructuring [sec_mda · as of 2024-08-13].
Sources: Pipeline · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Finch Therapeutics Group, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Finch Therapeutics Group, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
11.7 months
D/E 2.21 · 0% dilution
Lead: Preclinical
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 22, 2026- % of float
- 2.8%
- Days to cover
- 0.2
- Shares short
- 19,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FNCHQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Finch Therapeutics Group, Inc.?
Finch Therapeutics Group, Inc. is a microbiome technology company that has discontinued its lead clinical program and shifted focus to monetizing its intellectual property estate, with no current expectation of advancing product candidates or generating product revenue.
What is Finch Therapeutics Group, Inc.'s lead drug candidate?
Finch Therapeutics Group, Inc.'s most advanced tracked candidate is cp101 (Preclinical) for recurrent C. difficile infection.
Who is the CEO of Finch Therapeutics Group, Inc.?
Mr. Matthew P. Blischak J.D. is the chief executive officer of Finch Therapeutics Group, Inc. (FNCHQ).
Where is Finch Therapeutics Group, Inc. headquartered?
Finch Therapeutics Group, Inc. (FNCHQ) is headquartered in Boston, MA, United States.
What therapeutic areas does Finch Therapeutics Group, Inc. focus on?
Finch Therapeutics Group, Inc. develops therapies across Neurology, Immunology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.